Alzheimer’s therapies could result in $12B market by 2023

The industry for Alzheimer’s drug treatments is expected to grow from modest beginnings to big business in the next decade, according to a June report by Decision Resources Group.

The analysis estimates that the market for Alzheimer’s therapies will more than triple by 2023 to $12 billion, driven by disease-modifying therapies including monoclonal antibody compounds that work to counter beta-amyloid in the brain.

Two therapies have already emerged in the research—solanezumab produced by Eli Lilly and gantenerumab by Roche. The BACE inhibitor MK-8931 produced in partnership between MorphoSys, Chugai and Roche is also showing promise.

The report notes that these therapies could bring in sales of $7 billion per estimated cost in 2023. The main emerging markets appear to be the U.S., Japan and Western Europe, including France, Spain, Italy and Germany.

Another agent, the adjunctive symptomatic Lu-AE58054 from Lundbeck and Otsuka is also expected to do well with an estimated 10 percent of the market cornered in 2023. According to the report, Lilly’s solanezumab could enter the market as early as 2018.